AJTMH HINARI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 53(6), 1995, pp. 648-651
Copyright © 1995 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Asilian, A.
Right arrow Articles by Olliaro, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Asilian, A.
Right arrow Articles by Olliaro, P.

A Randomized, Placebo-Controlled Trial of a Two-Week Regimen of Aminosidine (Paromomycin) Ointment for Treatment of Cutaneous Leishmaniasis in Iran

A. Asilian, T. Jalayer, J. A. G. Whitworth, R. L. Ghasemi, M. Nilforooshzadeh AND P. Olliaro
Departments of Dermatology and Parasitology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; London School of Hygiene and Tropical Medicine, London, United Kingdom; Farmitalia-Carlo Erba, Research and Development, Anti-Infectives, Milan, Italy

The effect of a two-week regimen of topical aminosidine was investigated in a randomized, double-blind, placebo-controlled trial of 251 selected Iranian patients with zoonotic cutaneous leishmaniasis. Patients underwent clinical and parasitologic assessment before and 15 (end of therapy), 45, and 105 days after starting the treatment. Aminosidine ointment was safe and well-tolerated, and produced significant reductions in the prevalence of parasitologically positive smears on days 15 and 105 (but not day 45) after treatment compared with placebo. However, there was no clear clinical benefit at any stage after treatment. We conclude that this twice a day two-week regimen of aminosidine was inadequate to accelerate the recovery of most cases of cutaneous leishmaniasis. However, the ointment did show some clear evidence of parasitologic efficacy and should now be studied in longer or more frequent regimes in an effort to prevent parasitologic relapse and thus promote clinical improvement.




This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
T. Garnier, A. Mantyla, T. Jarvinen, J. Lawrence, M. Brown, and S. Croft
In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs
J. Antimicrob. Chemother., October 1, 2007; 60(4): 802 - 810.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
G. MORIZOT, P. DELGIUDICE, E. CAUMES, E. LAFFITTE, P. MARTY, A. DUPUY, C. SARFATI, S. HADJ-RABIA, H. DARIE, A.-S. LE GUERN, et al.
HEALING OF OLD WORLD CUTANEOUS LEISHMANIASIS IN TRAVELERS TREATED WITH FLUCONAZOLE: DRUG EFFECT OR SPONTANEOUS EVOLUTION?
Am J Trop Med Hyg, January 1, 2007; 76(1): 48 - 52.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Blum, P. Desjeux, E. Schwartz, B. Beck, and C. Hatz
Treatment of cutaneous leishmaniasis among travellers
J. Antimicrob. Chemother., February 1, 2004; 53(2): 158 - 166.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. Zvulunov, S. Klaus, D. Vardy, A. A. Alrajhi, E. B. De Vol, and J. H. Maguire
Fluconazole for the Treatment of Cutaneous Leishmaniasis
N. Engl. J. Med., August 1, 2002; 347(5): 370 - 371.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Society of Tropical Medicine and Hygiene.